reports
EQS-News: MedMira provides Progress Update
EQS-News: MedMira Inc. MedMira provides Progress Update 03.10.2022 / 13:04 CET/CEST The issuer is solely responsible for the content of this announcement. Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market.U.S. Regulatory Update on COVID-19 ProductsThe recent announced recommendation by the U.S. FDA to IVD manufacturers to apply for the traditional regulatory path 510(k) approval outlines the continuous need for qua...
VYRA™ Product Line Update
VYRA™ Product Line Update HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10th of May 2022, Health Canada issued to all stakeholder further information about the current Interim Order No. 3. As a result, the regulators have clearly defined the pathway to achieve the Interim Order and with it provided the Company with the last requirement to complete its final application for their review. The final condition for MedMira is to complete an addit...
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Anti...
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). This approval allows the Company to further strengthen its product offering in all markets accepting the CE mark. By utilizing its unique RVF technology®, MedMira offers the only commercially available combined screening and confirmation te...
MedMira gibt exklusive Vertriebspartnerschaft mit Webb Diagnostic Tech...
MedMira gibt exklusive Vertriebspartnerschaft mit Webb Diagnostic Technologies für Gesamtantikörpertest REVEALCOVID-19™ in den USA und erste Bestellung bekannt HALIFAX, Nova Scotia, May 28, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) gibt bekannt, dass das Unternehmen für den Vertrieb des Gesamtantikörpertests REVEALCOVID-19™ eine exklusive Vertriebsvereinbarung mit Webb Diagnostic Technologies, Inc. (WebbDX) abgeschlossen hat. Webb Diagnostic Technologies hat seine erste Bestellung im Wert von ca. 3,5 Millionen CAD aufgegeben. MedMira hat eine Anzahlung erhalten, um den ...
MedMira annonce un partenariat de distribution exclusive avec Webb Dia...
MedMira annonce un partenariat de distribution exclusive avec Webb Diagnostic Technologies et une commande initiale pour son test global de détection d'anticorps REVEALCOVID-19™ aux États-Unis HALIFAX, Nouvelle-Écosse, 28 mai 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV : MIR) annonce la conclusion d'un accord de distribution exclusive avec Webb Diagnostic Technologies, Inc., (WebbDX) pour la distribution du test global de détection d'anticorps REVEALCOVID-19™ de MedMira. Webb Diagnostic Technologies a passé la première commande d'une valeur d'achat d'environ 3,5 millions de doll...
MedMira Announces Exclusive Distribution Partnership with Webb Diagnos...
MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S. HALIFAX, Nova Scotia, May 27, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down pa...
MedMira gibt Fortschrittsbericht zu seinem REVEALCOVID-19â„¢-Gesamtant...
MedMira gibt Fortschrittsbericht zu seinem REVEALCOVID-19™-Gesamtantikörpertest einschließlich CE-Kennzeichnung bekannt Halifax, Nova Scotia (Kanada), May 22, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) hat heute bekanntgegeben, dass das Unternehmen den Registrierungsprozess abgeschlossen hat und sein REVEALCOVID-19™-Gesamtantikörperschnelltest nun mit der CE-Kennzeichnung (Conformité Européene) versehen ist. MedMira erklärt die Konformität mit allen wesentlichen in der Richtlinie 98/79/EG über In-vitro-Diagnostika festgehaltenen Anforderungen. Das Registrierungszertifikat...
MedMira fait un point sur les progrès réalisés concernant REVEALCOV...
MedMira fait un point sur les progrès réalisés concernant REVEALCOVID-19™, son test global pour la détection d'anticorps, comprenant l'apposition du marquage CE HALIFAX, Nouvelle-Écosse, 22 mai 2020 (GLOBE NEWSWIRE) -- Aujourd'hui, MedMira Inc. (MedMira) (TSXV : MIR) a annoncé avoir terminé le processus d'enregistrement et d'apposition du marquage CE (Conformité européenne) concernant son test global rapide de détection d'anticorps, REVEALCOVID-19™. MedMira déclare une conformité à toutes les exigences essentielles énoncées dans la Directive 98/79/CE pour les dispositifs médicaux de diagn...
MedMira Announces Progress Update of its REVEALCOVID-19â„¢ Total Antib...
MedMira Announces Progress Update of its REVEALCOVID-19™ Total Antibody Test Including CE Mark HALIFAX, Nova Scotia, May 21, 2020 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID-19™ Total Antibody Test. MedMira declares conformity to all essential requirements outlined in the In Vitro Diagnostic Medical Devices Directive 98/79/EC. The Certificate of Registration has been obtained from the European Authorized Representative and the product is now re...
MedMira annonce une mise à jour concernant le développement de son t...
MedMira annonce une mise à jour concernant le développement de son test de détection d'anticorps sur le lieu de soins HALIFAX, Nouvelle-Écosse, 20 avr. 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV : MIR) a annoncé aujourd'hui avoir achevé le développement de la solution de test sérologique sur le lieu de soins (Point of Care, POC) avec résultat immédiat. Basé sur la technologie unique et brevetée Rapid Vertical Flow® (RVF) de MedMira, le nouveau test REVEALCOVID-19TM fournit des résultats immédiats sans avoir besoin d'équipements supplémentaires tels qu'un lecteur ou un minuteur....
MedMira gibt ein Update zur Entwicklung eines Point-of-Care-Antikörpe...
MedMira gibt ein Update zur Entwicklung eines Point-of-Care-Antikörpertests bekannt HALIFAX, Nova Scotia, April 20, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), hat heute bekanntgegeben, dass es die Entwicklung einer serologischen Point-of-Care-(POC)-Testlösung mit sofort bereitstehendem Ergebnis abgeschlossen hat. Basierend auf der einzigartigen und patentierten Rapid Vertical Flow®-(RVF)-Technologie von MedMira liefert der neu entwickelte REVEALCOVID-19™ sofortige Ergebnisse, ohne dass zusätzliche Geräte wie ein Lesegerät oder ein Timer erforderlich sind. Für das Produkt...
MedMira Announces Update on Development of Point-of-Care Antibody Test
MedMira Announces Update on Development of Point-of-Care Antibody Test HALIFAX, Nova Scotia, April 17, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow® (RVF) technology, the newly developed REVEALCOVID-19TM delivers immediate results without the need for any additional equipment such as a reader or a timer. The product is subject to obtaining regulatory approvals to sell in the selected ...
MedMira Announces AGM Results
MedMira Announces AGM Results HALIFAX, Nova Scotia, June 03, 2019 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) held its 2019 Annual General Meeting of Shareholders on May 31, 2019 in Halifax, Nova Scotia. Incumbent Director Mr. Hermes Chan was re-elected and Mr. Jianhe Mao and Mr. Steven Cummings were elected to the Board during the meeting. Dr. Shou-Ching Tang and Ms. Lili Zhao chose not to stand for re-election to the MedMira Board of Directors. Mr. Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland, focusing on assisting European compa...
MedMira Reports Third Quarter Results
MedMira Reports Third Quarter Results HALIFAX, Nova Scotia, June 29, 2018 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2018. Q3 FY2018 Financial Results Highlights Profit and Loss Revenue: The Company recorded revenues in Q3 FY2018 of $76,360 compared to $192,590 in Q3 FY2017. The slight decrease in revenue was due to the Company’s strategy to focus on high profit margin markets. As outlined below, this strategy has resulted in the Company recording a higher contribution margin and has also indirectly de...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.